Invivyd Reports Preliminary Fourth Quarter 2025 Revenue and Recent Business Highlights GlobeNewswire January 08, 2026 Preliminary Q4 2025 PEMGARDA(R) (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth quarter-over-quarter Preliminary ending 2025 cash and cash equivalents of $226.7 million after raising over $200 million from financing transactions in 2H 2025 […]

(Other OTC:ONAR),(OTC US:ONAR), Miami, FL, Jan. 08, 2026 (GLOBE NEWSWIRE) — ONAR Holding Corporation (OTCQB: ONAR) (“ONAR” or the “Company”), an AI-powered marketing platform that acquires and scales specialist agencies, today announced that its subsidiary, ONAR, LLC, completed the sale of substantially all of the assets of VMED Services, LLC, which conducted operations under the

(NASDAQ:SMPL),(NASDAQ:SMPL.W), DENVER, Jan. 08, 2026 (GLOBE NEWSWIRE) — The Simply Good Foods Company (Nasdaq: SMPL) (“Simply Good Foods,” or the “Company”), a leader in the Nutritional Snacking Category, today reported financial results for the thirteen weeks ended November 29, 2025. First Quarter Summary:(1) Net sales of $340.2 million versus $341.3 million Net income of $25.3

Microchip Releases Custom Firmware For NVIDIA DGX Spark For Its MEC1723 Embedded Controllers Solution delivers secure boot, power management and system control for complex computing GlobeNewswire January 08, 2026 CHANDLER, Ariz., Jan. 08, 2026 (GLOBE NEWSWIRE) — Microchip Technology (Nasdaq: MCHP) has announced the release of custom-designed firmware for its MEC1723 Embedded Controller (EC), specifically

SUNRISE, Fla., Jan. 08, 2026 (GLOBE NEWSWIRE) — Transpire Bio announced today that its Chief Executive Officer, Dr. Xian-Ming Zeng, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 15, 2026 at 8:00 am Pacific Time. About Transpire Bio Inc.Transpire Bio Inc. is an integrated, US-based, revenue-generating, clinical-stage

(NasdaqGM:CLYM), First patients dosed in budoprutug PrisMN Phase 2 trial in pMN, with initial data expected second half 2026 Dosing ongoing in budoprutug Phase 1b/2a trial in ITP and Phase 1b trial in SLE; achieved regulatory clearance for SLE IND in China First patients dosed in CLYM116 Phase 1 healthy volunteer study Anticipating a data-rich

(NASDAQ:AVIR), Phase 3 Topline Results for Potential Best-in-Class Regimen for Treatment of HCV on Track for 2026 Topline Results from North American Phase 3 C-BEYOND Trial Expected Mid-2026; Results from C-FORWARD Trial Outside North America Expected Year-End 2026 C-BEYOND and C-FORWARD Are the First Global Phase 3 Head-to-Head Trials of Direct-Acting Antivirals for Treatment of

(NASDAQ:LTRX), IRVINE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) — Lantronix Inc. (NASDAQ: LTRX), a global leader in compute and connectivity IoT solutions powering Edge AI applications, today announced that it will attend the 28th Annual Needham Growth Conference, held at the Lotte NY Palace Hotel in New York City. Lantronix CEO Saleel Awsare and CFO

(NASDAQ:CGEM), Data readouts planned for CLN-978 across all three autoimmune indications in 2026, including single dose and repeat dosing data Company to complete monotherapy expansion cohorts to determine recommended Phase 2 dose for CLN-049 pivotal registrational study and initiate combination study in frontline AML in Q4 2026 Zipalertinib rolling NDA submission expected to be complete

(TSX:TLG),(OTC US:CHXMF),(Other OTC:CHXMF),(Boerse Frankfurt – Freiverkehr:CM5R), MONTREAL, Jan. 08, 2026 (GLOBE NEWSWIRE) — Troilus Mining Corp. (TSX: TLG; OTCQX: CHXMF; FRA: CM5) (“Troilus” or the “Company”), is pleased to provide a review of its key accomplishments in 2025 and an outlook for 2026, as the Company advances its flagship Troilus copper-gold project (the “Project”) through